Close interaction seen between blood vessel development and fat tissue formation

October 02, 2003

The key physiological processes of angiogenesis, the growth of new blood cells, and adipogenesis, the development and growth of fat cells, appear to be so closely interwoven that interfering with one process also halts the other. These findings from researchers at Massachusetts General Hospital (MGH) could eventually help to solve problems ranging from cancer, to obesity, to the development of replacement organs. The study, which will be printed in the Oct. 31 issue of Circulation Research, is being published via the journal's website on Oct. 2.

"It really looks like angiogenesis and adipogenesis are joined at the hip," says Rakesh K. Jain, PhD, director of the Steele Laboratory for Tumor Biology at MGH, senior author of the study, "These new findings are helping us understand just how closely these processes work together and identify new ways of controlling these functions to meet important medical challenges."

Previous research had suggested connections between these two processes. A 2002 study from the laboratory of angiogenesis pioneer Judah Folkman, MD, at Children's Hospital Boston found that when anti-angiogenesis agents were given to mice genetically programmed to develop obesity, the mice did not gain weight. The current MGH study reveals the mechanism behind this interaction.

Led by three investigators from the Steele Laboratory at MGH - Dai Fukumura, MD, PhD, Akira Ushiyama, PhD, and Dan Duda, DMD, PhD - the research team began examining the process by which fat-cell precursors called preadipocytes differentiate into mature adipocytes (fat cells). They first implanted normal preadipocytes into chambers beneath the skin of immune-deficient mice, and as expected the cells differentiated into mature fat cells. But not only did blood vessels develop to supply the growing tissue, they also formed efficient, organized networks, something that rarely happens outside of natural growth conditions.

"We've been trying to grow organized, mature blood vessel networks for more than 25 years," says Jain, "and this is the first time I've seen that happen under experimental conditions."

To block fat-cell differentiation, the researchers implanted mice with preadipocytes that had an inactivated form of a protein required for fat cells to mature. Not only did the implants neither grow nor differentiate into mature fat cells, but there also was virtually no blood vessel development. Similarly, introduction of an antibody against a protein key to angiogenesis both prevented blood vessel development in the implants and also kept the fat cell precursors from maturing.

"These processes now appear to be coupled at very fundamental levels," Jain says. "And we are starting to identify the proteins involved and the stages at which they are active." Jain is the A. Werk Cook Professor of Radiation Oncology at Harvard Medical School.

Better understanding of the interaction between angiogenesis and adipogenesis and the development of ways to control and direct the processes could have a wide range of medical applications. Anti-angiogenesis compounds are already being evaluated as cancer-fighters, and the current results suggest they may be useful in combating obesity as well. The observation that blood vessels growing in response to adipogenesis form organized networks - in contrast to the inefficient networks that develop in and around tumors - might help with efforts to grow new organs and tissues, since the development of a circulatory system is a key challenge in the field of tissue engineering.

Fukumura, Duda and Ushiyama - who is now with the National Institute of Public Health in Tokyo - are co-first authors of the Circulation Research paper; other co-authors are Lei Xu, MD, PhD, Joshua Tam, BS, and Igor Garkavtsev, MD, PhD, of the Steele Lab at MGH, and Krishna Chatterjee, PhD, of the University of Cambridge, England. The study was supported by grants from the National Institutes of Health.
-end-
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $350 million and major research centers in AIDS, cardiovascular research, cancer, cutaneous biology, medical imaging, neurodegenerative disorders, transplantation biology and photomedicine. In 1994, MGH and Brigham and Women's Hospital joined to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups, and nonacute and home health services.

Massachusetts General Hospital

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.